If the half-life is five days, you might wonder why the dose isnt given every five days
Huck et al., 2015
GLP-1 receptor agonists Primary mechanism(s) of action Increase glucose-dependent insulin secretion, reduce post-prandial glucagon, and delay gastric emptying (resulting in reduced after meal glucose levels and increased satiety) Examples Exenatide (Byetta 10 mcg Pen, Byetta 5 mcg Pen, Bydureon BCise 2 mcg Pen) Dosage Immediate release (Byetta) Initial: 5 mcg subcutaneous injection twice daily a maximum of 60 minutes before morning and evening meals, or before the two main meals of the day Maximum: 10 mcg subcutaneous injection twice daily a maximum of 60 minutes before morning and evening meals, or before the two main meals of the day Extended release (Bydureon BCise) Initial: 2 mg subcutaneous injection once weekly Maximum: 2 mg subcutaneous injection weekly Lixisenatide (Adlyxin) Short-acting Dosage Initial: 10 mcg subcutaneous injection once daily, up to one hour before the first meal of the day, for 14 days
To get around this, many people used to rely on intravenous (IV) therapy, which is effective but expensive and invasive
Compliance is inconsistent
BENEFIT FROM OUR PEPTIDE THERAPY Peptides have been used therapeutically since the early 1920s
.png)
.png)
